Novel Pentapeptide Derived from Chicken by-Product
Ameliorates DSS-Induced Colitis by Enhancing Intestinal Barrier Function
via AhR-Induced Src Inactivation
posted on 2020-11-19, 16:37authored byShanshan Li, Bin Ma, Jin Wang, Hengying Peng, Meng Zheng, Wenling Dai, Jihua Liu
Managing patients with refractory
inflammatory bowel diseases (IBD)
is a common clinical challenge. Galli Gigeriae Endothelium Corneum
(GGEC), a chicken by-product, has been used for centuries in Asian
countries as a functional food and supplement for the treatment of
gastrointestinal disorders. In this study, a novel peptide (LNLYP,
LP-5) with gastrointestinal stability that can enhance the intestinal
barrier function that was first identified in GGEC. Our work demonstrated
that aryl hydrocarbon receptor (AhR) activation by LP-5 could inhibit
the Src kinase to increase tight junction protein levels and down-regulate
the expression of inflammatory cytokines to protect the intestinal
barrier and finally alleviate dextran sulfate sodium (DSS)-induced
colitis. This study revealed that LP-5 had the potential to develop
into a therapeutic agent for the treatment of colitis and provided
new high-valued utilization of GGEC.